| 1 |
novel oral anticoagulants
(577 times)
|
Cardiology
(151 times)
|
AF (191 times)
VKAs (98 times)
VTE (69 times)
|
2012 Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
|
| 2 |
non-vitamin K antagonist oral anticoagulants
(548 times)
|
Cardiology
(185 times)
|
AF (258 times)
VKAs (83 times)
NVAF (56 times)
|
2013 Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
|
| 3 |
non-vitamin K oral anticoagulants
(183 times)
|
Cardiology
(50 times)
|
AF (73 times)
VKAs (31 times)
OAC (16 times)
|
2014 Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
|
| 4 |
non-vitamin K antagonist OACs
(8 times)
|
Cardiology
(3 times)
|
AF (6 times)
OACs (5 times)
OAC (3 times)
|
2015 Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
|
| 5 |
new oral anticoagulant drugs
(7 times)
|
Medicine
(2 times)
|
AF (2 times)
VKA (2 times)
AC (1 time)
|
2013 [Pulmonary embolism due to interaction between rivaroxaban and carbamazepine].
|
| 6 |
novel OACs
(4 times)
|
Cardiology
(3 times)
|
OAC (3 times)
ACS (1 time)
AEs (1 time)
|
2013 The hidden costs of anticoagulation in hospitalized patients with non-valvular atrial fibrillation.
|
| 7 |
new OACs
(3 times)
|
Cardiology
(1 time)
|
OAC (2 times)
AF (1 time)
FXa (1 time)
|
2013 Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
|
| 8 |
New-generation oral anticoagulants
(3 times)
|
Cardiology
(1 time)
|
GI (1 time)
MPV (1 time)
PDW (1 time)
|
2015 Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management.
|
| 9 |
non-VKA OACs
(3 times)
|
Internal Medicine
(2 times)
|
AF (3 times)
OAC (3 times)
VKAs (2 times)
|
2015 Choosing the right drug to fit the patient when selecting oral anticoagulation for stroke prevention in atrial fibrillation.
|
| 10 |
new direct OACs
(2 times)
|
Clinical Laboratory Techniques
(1 time)
|
AF (1 time)
HF (1 time)
ICH (1 time)
|
2014 Treatment of intracerebral hemorrhage associated with new oral anticoagulant use: the neurologist's view.
|
| 11 |
new orally active anticoagulants
(2 times)
|
Cardiac Surgical Procedures
(1 time)
|
AF (1 time)
DVT (1 time)
PE (1 time)
|
2013 New orally active anticoagulants in critical care and anesthesia practice: the good, the bad and the ugly.
|
| 12 |
non-vitamin K OACs
(2 times)
|
Therapeutics
(1 time)
|
ACS (1 time)
AF (1 time)
DAPT (1 time)
|
2019 Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances.
|
| 13 |
(VKAs)-non-VKA oral anticoagulants
(1 time)
|
Medicine
(1 time)
|
NMA (1 time)
RCTs (1 time)
RWD (1 time)
|
2019 Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings.
|
| 14 |
antagonist oral anticoagulants
(1 time)
|
Hematology
(1 time)
|
MMAS (1 time)
PDT (1 time)
|
2020 NOAC Adherence of Patients with Atrial Fibrillation in the Real World: Dosing Frequency Matters?
|
| 15 |
new US Food and Drug Administration-approved oral anticoagulants
(1 time)
|
Medicine
(1 time)
|
RCTs (1 time)
RR (1 time)
|
2014 Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients.
|
| 16 |
non-VKA oral ACs
(1 time)
|
Cardiology
(1 time)
|
AC (1 time)
AF (1 time)
AP (1 time)
|
2017 Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
|
| 17 |
NOS-containing amacrine cells
(1 time)
|
Neurology
(1 time)
|
GCs (1 time)
IR (1 time)
NO (1 time)
|
2010 Light responses and morphology of bNOS-immunoreactive neurons in the mouse retina.
|
| 18 |
Novel anticoagulations
(1 time)
|
Cardiology
(1 time)
|
VKAs (1 time)
|
2017 Uncertainty on the effectiveness and safety of rivaroxaban in premenopausal women with atrial fibrillation: empirical evidence needed.
|
| 19 |
novel orally administered anticoagulant agents
(1 time)
|
Gynecology
(1 time)
|
---
|
2016 Managing novel orally administered anticoagulants in patients undergoing urogynaecological surgery.
|
| 20 |
number of other oral medications
(1 time)
|
Neoplasms
(1 time)
|
BNHO (1 time)
DGP (1 time)
LMWH (1 time)
|
2016 Practice Patterns for Prophylaxis and Treatment of Venous Thromboembolism in German Cancer Patients.
|
A Search Service for Abbreviation / Long Form